Clinical trial · Interventional
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
NCT00351962CI-TRIAL-00029629completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Medically inoperable lung cancer or metastatic lung tumours will be treated with fractionated stereotactic radiation using a schedule of 1) 12 Gy x 4 treatments or 2) 6 Gy x 10 treatments.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fractionated Stereotactic Radiotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Schedule I (10 fractions)
- description
- Subjects will receive a total of 10 stereotactic radiation treatments, given over 3 weeks.
- interventionNames
- Procedure: Fractionated Stereotactic Radiotherapy
- type
- EXPERIMENTAL
- label
- Schedule II (4 fractions)
- description
- Subjects will receive a total of 4 stereotactic radiation treatments, given over 2 weeks.
- interventionNames
- Procedure: Fractionated Stereotactic Radiotherapy
Primary outcomes (1)
- measure
- Dose-limiting toxicity as defined by CTCAE V3 grade 4 or 5.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * non-small cell lung cancer less than 6cm; no mediastinal or distant metastases * Open to Alberta,Canada Residents Exclusion Criteria: * tumour size greater than 6cm; inadequate pulmonary function(ie. FEV1 less than 0.8 L), Karnofsky performance status less than 70, multiple co-morbid conditions
References
Publications (0)
Data not yet available
No reference posted for this study.